Translating TRAIL-receptor targeting agents to the clinic

被引：66
|
作者：
den Hollander, Martha W. [1 ]
Gietema, Jourik A. [1 ]
de Jong, Steven [1 ]
Walenkamp, Annemiek M. E. [1 ]
Reyners, Anna K. L. [1 ]
Oldenhuis, Corina N. A. M. [1 ]
de Vries, Elisabeth G. E. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
来源：
CANCER LETTERS | 2013年 / 332卷 / 02期
关键词：
TRAIL; Clinical studies; Biomarkers; APOPTOSIS-INDUCING LIGAND; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; PHASE-I; FUSION PROTEIN; TUMOR-GROWTH; MAPATUMUMAB; COMBINATION; TRIAL; LEXATUMUMAB;
D O I：
10.1016/j.canlet.2012.04.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：194 / 201
页数：8
相关论文
共 50 条
  • [41] Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells
    Oh, Y.
    Jeon, Y-J
    Hong, G-S
    Kim, I.
    Woo, H-N
    Jung, Y-K
    [J]. CELL DEATH AND DIFFERENTIATION, 2012, 19 (07): : 1196 - 1207
  • [42] Development of molecular agents for IGF receptor targeting
    Salisbury, AJ
    Macaulay, VM
    [J]. HORMONE AND METABOLIC RESEARCH, 2003, 35 (11-12) : 843 - 849
  • [43] Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells
    Y Oh
    Y-J Jeon
    G-S Hong
    I Kim
    H-N Woo
    Y-K Jung
    [J]. Cell Death & Differentiation, 2012, 19 : 1196 - 1207
  • [44] Clinically used agents to induce apoptosis especially targeting the TRAIL-receptors
    de Vries, E. G. E.
    de Jong, S.
    Mom, C. H.
    Gietema, J. A.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 3 - 3
  • [45] Targeting androgen receptor and trail:a novel treatment paradigm for breast cancer
    Ya-ping TU
    Yan XIE
    Peter W ABEL
    Tao-tao WEI
    Xu LUO
    [J]. 中国药理学与毒理学杂志, 2017, 31 (10) : 954 - 954
  • [46] Targeting Androgen Receptor and TRAIL: A Novel Treatment Paradigm for Breast Cancer
    Xie, Yan
    Chen, Linjie
    Abel, Peter W.
    Wei, Taotao
    Luo, Xu
    Tu, Yaping
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [47] Translating statistics for use in the clinic
    Atkins, CD
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1997, 12 (10) : 626 - 628
  • [48] TRANSLATING THE CARDIAC PHYSIOME INTO THE CLINIC
    Smith, Nicolas Peter
    Niederer, Steven A.
    Nordsleten, David A.
    McCormick, Mathew
    Rhode, Kawal
    Razavi, Reza
    [J]. JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 101 - 101
  • [49] Translating statistics for use in the clinic
    Carl D. Afkins
    [J]. Journal of General Internal Medicine, 1997, 12 : 626 - 628
  • [50] ABBV-621: A best-in-class TRAIL-receptor agonist fusion protein that enhances optimal clustering for the treatment of solid and hematologic tumors
    Morgan-Lappe, Susan E.
    [J]. CANCER RESEARCH, 2017, 77
12345